Competitor Analysis: COVID-19 Vaccines in Development
Competitor Analysis: COVID-19 Vaccines in Development
This Competitive Intelligence report about COVID-19 Vaccines in Development describes the landscape of industry-driven approaches to discover and develop vaccines for prevention of COVID-19 as of March 27, 2020.
COVID-19 is caused by SARS-CoV-2, which belongs to a group of viruses called coronaviruses that attack the respiratory system. There is currently no licensed vaccine, treatment or cure for COVID-19. Since the outbreak of the SARS-CoV-2 pandemia, industry alone or in collaborative efforts rapidly have initiated work to generate vaccine candidates to prevent COVID-19 based on a variety of technologies, including
- mRNA
- vector/vectorized cells
- DNA
- recombinant subunit
- live, attenuated virus
- different adjuvants
Clinical evaluation of the first COVID-19 vaccine candidates has begun and a total at least 34 vaccine approaches to prevent COVID-19 are in the pipeline.
This report includes a compilation of industry-driven projects in research and development of SARS-CoV-2 targeted vaccines for prophylaxis of COVID-19. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced.